OLIG2 and glioblastoma: Twenty-two compounds of the 95 tested exhibited considerable potency against GBM cells in vitro, and were screened initially using tumorigenic Ink4a/arf EGFR-VIII mouse glioma stem cells because these cells express high levels of OLIG2 [33].